GABAergic modulation of secondary hyperalgesia: A randomized controlled 4-way crossover trial with the α2-subunit preferring GABA positive allosteric modulator, N-desmethyl-clobazam in healthy volunteers.
Journal
European journal of pain (London, England)
ISSN: 1532-2149
Titre abrégé: Eur J Pain
Pays: England
ID NLM: 9801774
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
23
09
2019
revised:
28
02
2020
accepted:
03
03
2020
pubmed:
15
3
2020
medline:
6
1
2021
entrez:
15
3
2020
Statut:
ppublish
Résumé
The antihyperalgesic and sedative effects of the α2-subunit preferring GABA
Substances chimiques
Benzodiazepines
12794-10-4
Clobazam
2MRO291B4U
gamma-Aminobutyric Acid
56-12-2
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1094-1106Subventions
Organisme : Swiss National Science Foundation
ID : SPUM33CM30_124117/1
Pays : Switzerland
Informations de copyright
© 2020 European Pain Federation - EFIC®.
Références
Attal, N., & Bouhassira, D. (2015). Pharmacotherapy of neuropathic pain: Which drugs, which treatment algorithms? Pain, 156(Suppl 1), S104-S114. https://doi.org/10.1097/01.j.pain.0000460358.01998.15
Attal, N., Cruccu, G., Baron, R., Haanpaa, M., Hansson, P., Jensen, T. S., … European Federation of Neurological Societies (2010). EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. European Journal of Neurology, 17(9), 1113-e1188. https://doi.org/10.1111/j.1468-1331.2010.02999.x
Ballantyne, J. C. (2017). Opioids for the treatment of chronic pain: Mistakes made, lessons learned, and future directions. Anesthesia and Analgesia, 125(5), 1769-1778. https://doi.org/10.1213/ANE.0000000000002500
Barnard, E. A. (2001). The molecular architecture of GABA-A receptor. In H. Möhler (Ed.), Pharmacology of GABA and glycine neurotransmisssion (pp. 79-99). Berlin: Springer.
Barnard, E. A., Skolnick, P., Olsen, R. W., Mohler, H., Sieghart, W., Biggio, G., … Langer, S. Z. (1998). International Union of Pharmacology. XV. Subtypes of gamma-aminobutyric acidA receptors: Classification on the basis of subunit structure and receptor function. Pharmacological Reviews, 50(2), 291-313.
Bennett, G. J. (2012). What is spontaneous pain and who has it? The Journal of Pain, 13(10), 921-929. https://doi.org/10.1016/j.jpain.2012.05.008
Besson, M., Brook, P., Chizh, B. A., & Pickering, A. E. (2005). Tactile allodynia in patients with postherpetic neuralgia: Lack of change in skin blood flow upon dynamic stimulation. Pain, 117(1-2), 154-161.https://doi.org/10.1016/j.pain.2005.05.036
Besson, M., Daali, Y., Di Lio, A., Dayer, P., Zeilhofer, H. U., & Desmeules, J. (2013). Antihyperalgesic effect of the GABA(A) ligand clobazam in a neuropathic pain model in mice: A pharmacokinetic-pharmacodynamic study. Basic & Clinical Pharmacology & Toxicology, 112(3), 192-197. https://doi.org/10.1111/bcpt.12017
Besson, M., Matthey, A., Daali, Y., Poncet, A., Vuillemier, P., Curatolo, M., … Desmeules, J. (2015). GABAergic modulation in central sensitization in humans: A randomized placebo-controlled pharmacokinetic-pharmacodynamic study comparing clobazam with clonazepam in healthy volunteers. Pain, 156(3), 397-404. https://doi.org/10.1097/01.j.pain.0000460331.33385.e8
Bickel, A., Dorfs, S., Schmelz, M., Forster, C., Uhl, W., & Handwerker, H. O. (1998). Effects of antihyperalgesic drugs on experimentally induced hyperalgesia in man. Pain, 76(3), 317-325. https://doi.org/10.1016/S0304-3959(98)00062-1
Bishop, T., Ballard, A., Holmes, H., Young, A. R., & McMahon, S. B. (2009). Ultraviolet-B induced inflammation of human skin: Characterisation and comparison with traditional models of hyperalgesia. European Journal of Pain, 13(5), 524-532. https://doi.org/10.1016/j.ejpain.2008.06.006
Bosilkovska, M., Clement, M., Dayer, P., Desmeules, J., & Daali, Y. (2014). Incorporation of flurbiprofen in a 4-drug cytochrome P450 phenotyping cocktail. Basic & Clinical Pharmacology & Toxicology, 115(5), 465-466. https://doi.org/10.1111/bcpt.12231
Cruccu, G., & Truini, A. (2017). A review of neuropathic pain: From guidelines to clinical practice. Pain and Therapy, 6(Suppl 1), 35-42. https://doi.org/10.1007/s40122-017-0087-0
de Leon, J., Spina, E., & Diaz, F. J. (2013). Clobazam therapeutic drug monitoring: A comprehensive review of the literature with proposals to improve future studies. Therapeutic Drug Monitoring, 35(1), 30-47. https://doi.org/10.1097/FTD.0b013e31827ada88
Di Lio, A., Benke, D., Besson, M., Desmeules, J., Daali, Y., Wang, Z. J., … Zeilhofer, H. U. (2011). HZ166, a novel GABAA receptor subtype-selective benzodiazepine site ligand, is antihyperalgesic in mouse models of inflammatory and neuropathic pain. Neuropharmacology, 60(4), 626-632. https://doi.org/10.1016/j.neuropharm.2010.11.026
Finnerup, N. B., Attal, N., Haroutounian, S., McNicol, E., Baron, R., Dworkin, R. H., … Wallace, M. (2015). Pharmacotherapy for neuropathic pain in adults: A systematic review and meta-analysis. The Lancet Neurology, 14(2), 162-173. https://doi.org/10.1016/S1474-4422(14)70251-0
Gurrell, R., Dua, P., Feng, G., Sudworth, M., Whitlock, M., Reynolds, D. S., & Butt, R. P. (2018). A randomised, placebo-controlled clinical trial with the alpha2/3/5 subunit selective GABAA positive allosteric modulator PF-06372865 in patients with chronic low back pain. Pain, 159(9), 1742-1751. https://doi.org/10.1097/j.pain.0000000000001267
Gustorff, B., Anzenhofer, S., Sycha, T., Lehr, S., & Kress, H. G. (2004). The sunburn pain model: the stability of primary and secondary hyperalgesia over 10 hours in a crossover setting. Anesthesia & Analgesia, 98(1), 173-177, table of contents. https://doi.org/10.1213/01.ANE.0000093224.77281.A5
Gustorff, B., Hoechtl, K., Sycha, T., Felouzis, E., Lehr, S., & Kress, H. G. (2004). The effects of remifentanil and gabapentin on hyperalgesia in a new extended inflammatory skin pain model in healthy volunteers. Anesthesia & Analgesia, 98(2), 401-407, table of contents. https://doi.org/10.1213/01.ANE.0000095150.76735.5D
Gustorff, B., Sycha, T., Lieba-Samal, D., Rolke, R., Treede, R. D., & Magerl, W. (2013). The pattern and time course of somatosensory changes in the human UVB sunburn model reveal the presence of peripheral and central sensitization. Pain, 154(4), 586-597. https://doi.org/10.1016/j.pain.2012.12.020
Ing Lorenzini, K., Besson, M., Daali, Y., Salomon, D., Dayer, P., & Desmeules, J. (2011). A randomized, controlled trial validates a peripheral supra-additive antihyperalgesic effect of a paracetamol-ketorolac combination. Basic & Clinical Pharmacology & Toxicology, 109(5), 357-364. https://doi.org/10.1111/j.1742-7843.2011.00733.x
Ing Lorenzini, K., Besson, M., Daali, Y., Salomon, D., Dayer, P., & Desmeules, J. (2012). Validation of the simplified UVB model to assess the pharmacodynamics of analgesics in healthy human volunteers. CHIMIA International Journal for Chemistry, 66(5), 296-299. https://doi.org/10.2533/chimia.2012.296
Knabl, J., Witschi, R., Hosl, K., Reinold, H., Zeilhofer, U. B., Ahmadi, S., … Zeilhofer, H. U. (2008). Reversal of pathological pain through specific spinal GABAA receptor subtypes. Nature, 451(7176), 330-334. https://doi.org/10.1038/nature06493
Laux, G., & Koeppen, D. (1984). Serum and cerebrospinal fluid concentration of clobazam and N-desmethylclobazam. International Journal of Clinical Pharmacology, Therapy and Toxicology, 22(7), 355-359.
McNicol, E. D., Midbari, A., & Eisenberg, E. (2013). Opioids for neuropathic pain. Cochrane Database of Systematic Reviews, 29(8), CD006146. https://doi.org/10.1002/14651858.CD006146.pub2
Morch, C. D., Gazerani, P., Nielsen, T. A., & Arendt-Nielsen, L. (2013). The UVB cutaneous inflammatory pain model: A reproducibility study in healthy volunteers. International Journal of Physiology, Pathophysiology and Pharmacology, 5(4), 203-215.
Nutt, D. J., Besson, M., Wilson, S. J., Dawson, G. R., & Lingford-Hughes, A. R. (2007). Blockade of alcohol's amnestic activity in humans by an alpha5 subtype benzodiazepine receptor inverse agonist. Neuropharmacology, 53(7), 810-820. https://doi.org/10.1016/j.neuropharm.2007.08.008
Pullar, T., Edwards, D., Haigh, J. R., Peaker, S., & Feely, M. P. (1987). The effect of cimetidine on the single dose pharmacokinetics of oral clobazam and N-desmethylclobazam. British Journal of Clinical Pharmacology, 23(3), 317-321. https://doi.org/10.1111/j.1365-2125.1987.tb03051.x
Pullar, T., Haigh, J. R., Peaker, S., & Feely, M. P. (1987). Pharmacokinetics of N-desmethylclobazam in healthy volunteers and patients with epilepsy. British Journal of Clinical Pharmacology, 24(6), 793-797. https://doi.org/10.1111/j.1365-2125.1987.tb03247.x
Ralvenius, W. T., Acuna, M. A., Benke, D., Matthey, A., Daali, Y., Rudolph, U., … Besson, M. (2016). The clobazam metabolite N-desmethyl clobazam is an alpha2 preferring benzodiazepine with an improved therapeutic window for antihyperalgesia. Neuropharmacology, 109, 366-375. https://doi.org/10.1016/j.neuropharm.2016.07.004
Ralvenius, W. T., Benke, D., Acuna, M. A., Rudolph, U., & Zeilhofer, H. U. (2015). Analgesia and unwanted benzodiazepine effects in point-mutated mice expressing only one benzodiazepine-sensitive GABAA receptor subtype. Nature Communications, 6, 6803. https://doi.org/10.1038/ncomms7803
Rudolph, U., & Knoflach, F. (2011). Beyond classical benzodiazepines: Novel therapeutic potential of GABAA receptor subtypes. Nature Reviews Drug Discovery, 10(9), 685-697. https://doi.org/10.1038/nrd3502
Rupp, W., Badian, M., Christ, O., Hajdu, P., Kulkarni, R. D., Taeuber, K., … Vanderbeke, O. (1979). Pharmacokinetics of single and multiple doses of clobazam in humans. British Journal of Clinical Pharmacology, 7(S1), 51S-57S. https://doi.org/10.1111/j.1365-2125.1979.tb04665.x
Schmelz, M. (2009). Translating nociceptive processing into human pain models. Experimental Brain Research, 196(1), 173-178. https://doi.org/10.1007/s00221-009-1809-2
Schmelz, M. (2013a). Sensitized pain response to bradykinin after sunburn-A human model for ongoing inflammatory pain? Pain, 154(6), 769-770. https://doi.org/10.1016/j.pain.2013.03.018
Schmelz, M. (2013b). Sunburn-A human inflammatory pain model for primary and secondary hyperalgesia. Scandinavian Journal of Pain, 4(1), 38-39. https://doi.org/10.1016/j.sjpain.2012.11.006
Tappe-Theodor, A., & Kuner, R. (2014). Studying ongoing and spontaneous pain in rodents-challenges and opportunities. European Journal of Neuroscience, 39(11), 1881-1890. https://doi.org/10.1111/ejn.12643
van Amerongen, G., Siebenga, P. S., Gurrell, R., Dua, P., Whitlock, M., Gorman, D., … Groenenveld, G. J. (2019). Analgesic potential of PF-06372865, an alpha2/alpha3/alpha5 subtype-selective GABAA partial agonist, in humans. British Journal of Anaesthesia, 123(2), e194-e203. https://doi.org/10.1016/bja.2018.12.006
Vuilleumier, P. H., Besson, M., Desmeules, J., Arendt-Nielsen, L., & Curatolo, M. (2013). Evaluation of anti-hyperalgesic and analgesic effects of two benzodiazepines in human experimental pain: A randomized placebo-controlled study. PLoS ONE, 8(3), e43896. https://doi.org/10.1371/journal.pone.0043896
Zeilhofer, H. U. (2008). Loss of glycinergic and GABAergic inhibition in chronic pain-contributions of inflammation and microglia. International Immunopharmacology, 8(2), 182-187. https://doi.org/10.1016/j.intimp.2007.07.009
Zeilhofer, H. U., Benke, D., & Yevenes, G. E. (2012). Chronic pain states: Pharmacological strategies to restore diminished inhibitory spinal pain control. Annual Review of Pharmacology and Toxicology, 52, 111-133. https://doi.org/10.1146/annurev-pharmtox-010611-134636
Zeilhofer, H. U., Mohler, H., & Di Lio, A. (2009). GABAergic analgesia: New insights from mutant mice and subtype-selective agonists. Trends in Pharmacological Sciences, 30(8), 397-402. https://doi.org/10.1016/j.tips.2009.05.007